Fresh Pf/BNT press release on vaccine efficacy against Omikron
(check out #4/5 for CD8 T cell epitopes and severe disease!)
1/5
investors.biontech.de/news-releases/…
(check out #4/5 for CD8 T cell epitopes and severe disease!)
1/5
investors.biontech.de/news-releases/…
- preliminary laboratory studies...three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant..., while two doses show significantly reduced neutralization titers
2/5
2/5
- a third dose...increases...neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant
- titers after the booster...are comparable to titers...after two doses against the wild-type virus, which are associated with high levels of protection
3/5
- titers after the booster...are comparable to titers...after two doses against the wild-type virus, which are associated with high levels of protection
3/5
- As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease
4/5
4/5
- ...development of a variant-specific vaccine for Omicron...expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022
5/5
5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
